{ "items": [ "\n\n
\n \n 11 April 2022\n \n
\n\n \n \n \n\n \n \n \nThe company plans to develop Lilly\u2019s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
\n \n\n\n \n 6 April 2022\n \n
\n\n \n \n \n\n \n \n \nInitiation of Phase 1 Study marks PepGen\u2019s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
\n \n\n\n \n 31 March 2022\n \n
\n\n \n \n \n\n \n \n \nOSPT has been awarded \u00a3680K to advance its disruptive antibacterial technology.
\n \n\n\n \n 1 February 2022\n \n
\n\n \n \n \n\n \n \n \nThe BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.
\n \n\n\n \n 1 February 2022\n \n
\n\n \n \n \n\n \n \n \nIn December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.
\n \n\n\n \n 1 February 2022\n \n
\n\n \n \n \n\n \n \n \nAlethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multiomic technology to discover and develop life-changing treatments for patients with blood cancer.
\n \n\n\n \n 25 January 2022\n \n
\n\n \n \n \n\n \n \n \nThe research collaboration will investigate TPOXX\u00ae (tecovirimat) in combination with Bioarchitech\u2019s proprietary vaccinia-based immunotherapy platform in preclinical studies.
\n \n\n\n \n 3 January 2022\n \n
\n\n \n \n \n\n \n \n \nKyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
\n \n\n\n \n 14 December 2021\n \n
\n\n \n \n \n\n \n \n \nThe two companies share the same goals, to improve the lives of those dealing with liver disease.
\n \n\n\n \n 22 November 2021\n \n
\n\n \n \n \n\n \n \n \nHelping people get the answers they need to make more informed decisions across the cancer continuum.
\n \n\n\n \n 15 November 2021\n \n
\n\n \n \n \n\n \n \n \nCyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.
\n \n\n\n \n 5 November 2021\n \n
\n\n \n \n \n\n \n \n \nThe technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome\u2019s platform in the discovery of genetic targets for innovative precision medicine development.
\n \n\n\n \n 4 November 2021\n \n
\n\n \n \n \n\n \n \n \nExogene has been selected as one of ten innovative startup companies, working at the interface of biomedical and data science, to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme.
\n \n\n\n \n 1 November 2021\n \n
\n\n \n \n \n\n \n \n \nKyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
\n \n\n\n \n 22 October 2021\n \n
\n\n \n \n \n\n \n \n \nRecipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
\n \n\n\n \n 29 September 2021\n \n
\n\n \n \n \n\n \n \n \nThe inaugural Libra programme has been set up to support tech leadership teams with at least one Black or multiracial founder and to promote diversity and equal opportunities in the sector.
\n \n\n\n \n 1 September 2021\n \n
\n\n \n \n \n\n \n \n \nThe BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
\n \n\n\n \n 18 August 2021\n \n
\n\n \n \n \n\n \n \n \nDespite the disruption caused by the pandemic, BioEscalator companies attracted a record high of \u00a31.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.
\n \n\n\n \n 5 August 2021\n \n
\n\n \n \n \n\n \n \n \nProceeds to support expansion and advancement of PepGen\u2019s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
\n \n\n\n \n 23 July 2021\n \n
\n\n \n \n \n\n \n \n \nAfter a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
\n \n\n